ExoDx™ Prostate IntelliScore EPI CE-IVD

Introducing the only exosome-based prostate cancer test delivering a unique data point to help guide the prostate biopsy decision. The EPI‑CE test is a simple urine test, which is independent of PSA and other standard of care (SOC) information.

Person

Assess prostate cancer risk

Leverages the power of exosomes to detect disease earlier in the progression of prostate cancer

What is the EPI‑CE Test?

Bottle

Precisely predictive, clinically convenient

Simple urine test, non-DRE, independent molecular information to help guide the biopsy decision

Discover the EPI‑CE Test Today!

Stethoscope

A new standard in prostate risk assessment

Clinical studies demonstrate the EPI-CE test discriminates between high-grade and low-grade prostate cancer and benign disease

Publications and Abstracts

RNA DNA

A treasure trove of RNA, DNA and protein

Let us help you solve complex clinical and scientific challenges with liquid biopsy, exosome-based technology that is vastly superior to cfDNA and CTCs

What are Exosomes?

ExoDx™ Prostate IntelliScore EPI CE-IVD

The EPI-CE test is based on the well-established ExoDx™ Prostate test which has successfully operated from ExoDx’s CLIA facility in the US since 2016 and is reimbursed by several leading insurance providers.  Both tests share the same specimen requirements, exoRNA isolation methodology, RT-qPCR detection of biomarkers and algorithm for risk score calculation.  The EPI-CE test has been further developed for distribution and use in third-party clinical laboratories in the EU and comprises a ready-to-use CE-IVD assay reagent kit and cloud-based CE-IVD software to facilitate risk score calculation. 

Learn More About the EPI-CE Test

Meet the ExosomeDx Team

The EPI-CE test is a simple urine test that detects three important genomic biomarkers that are markers of high-grade prostate cancer. Using this assessment, the physician can determine whether or not a patient should undergo a diagnostic biopsy.

Gaining access to molecular information from biofluids without needing direct access to the tissue itself will have far-reaching implications in patient management. While our diagnostics are initially focused on cancer, our exosome-based technology platform is potentially applicable to other diseases or medical conditions where molecular testing is beneficial, but where access to tissue is difficult or impossible. 

"Understandably, having a prostate biopsy performed is associated with a great deal of anxiety for the patient. Practice shows that many biopsies are not performed even though a cancer would have been present. And at the same time, biopsies are performed that would not have been necessary. The Exosome test aids the biopsy decision enormously and increases confidence with both patients and physicians." - Dr. Mikkel Noerholm, Laboratory Director, Head of EU Operations:

 

Partner with Exosome Diagnostics

Meet Johan and Michael. "With what we know about exosomes, we are the perfect partners for helping pharma partners solve their research problems".

Dr. Johan Skog is the Chief Scientific Officer at ExosomeDx and one of the world’s first scientists to discover exosomes. He immediately saw the opportunity of analyzing the RNA transcriptome profile to stratify patients as to how they respond to treatment. Michael Valentino is Exosome Diagnostic's Scientific Director and knew from a young age he wanted to be part of changing the course of cancer treatment.